Biodexa Pharmaceuticals PLC
NASDAQ:BDRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Holmen AB
STO:HOLM B
|
SE |
Biodexa Pharmaceuticals PLC
Operating Income
Biodexa Pharmaceuticals PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biodexa Pharmaceuticals PLC
NASDAQ:BDRX
|
Operating Income
-£8.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$247.7m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£45.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Operating Income
-$179m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£83m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Operating Income
-£32.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-9%
|
|
Biodexa Pharmaceuticals PLC
Glance View
Biodexa Pharmaceuticals PLC is a GB-based company operating in Biotechnology industry. The company is headquartered in Abingdon, Oxfordshire and currently employs 27 full-time employees. The company went IPO on 2014-12-08. Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The firm is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others.
See Also
What is Biodexa Pharmaceuticals PLC's Operating Income?
Operating Income
-8.6m
GBP
Based on the financial report for Dec 31, 2025, Biodexa Pharmaceuticals PLC's Operating Income amounts to -8.6m GBP.
What is Biodexa Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 5Y
4%
Over the last year, the Operating Income growth was 6%. The average annual Operating Income growth rates for Biodexa Pharmaceuticals PLC have been 1% over the past three years , 4% over the past five years .
